2022
Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter‐Defibrillator Generator Changes
Bilchick KC, Wang Y, Curtis JP, Shadman R, Dardas TF, Anand I, Lund LH, Dahlström U, Sartipy U, Levy WC. Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter‐Defibrillator Generator Changes. Journal Of The American Heart Association 2022, 11: e023743. PMID: 35766293, PMCID: PMC9333379, DOI: 10.1161/jaha.121.023743.Peer-Reviewed Original ResearchConceptsSeattle Heart Failure ModelHeart failure modelHeart failure patientsResynchronization therapyGenerator changeSurvival benefitWorse survivalFailure patientsNational Cardiovascular Data Registry ICD RegistryGC survivalSurvival Benefit AssociatedPrimary prevention indicationVentricular ejection fractionAnnual mortalityICD therapyConclusions PatientsPrevention indicationEjection fractionICD RegistryImproved survivalPrimary preventionPatient deathGreater effect sizeLVEFPatients
2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?
Heidenreich PA, Tsai V, Bao H, Curtis J, Goldstein M, Curtis L, Hernandez A, Peterson P, Turakhia MP, Masoudi FA. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Failure 2015, 3: 497-504. PMID: 25982109, DOI: 10.1016/j.jchf.2015.01.012.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionICD implantationOlder patientsTrial criteriaNew York Heart Association functional class IIIAge groupsSocial Security Death IndexPatients age 85Receipt of CRTFunctional class IIICardiac resynchronization therapyVentricular ejection fractionClinical trial criteriaDifferent age groupsPatient ageEjection fractionICD RegistryImproved survivalPrimary outcomeResynchronization therapyTherapy useDeath IndexMean ageClinical trialsRegistry data